Halozyme Therapeutics Inc (HALO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 9.25 is considered Undervalued compared with the five-year average of 14.38. The fair price of Halozyme Therapeutics Inc (HALO) is between 97.35 to 151.68 according to relative valuation method. Compared to the current price of 69.40 USD , Halozyme Therapeutics Inc By Undervalued By 28.71%.

Relative Value

Fair Zone

97.35-151.68

Current Price：69.40

28.71%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Halozyme Therapeutics Inc (HALO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Halozyme Therapeutics Inc (HALO) has a current Price-to-Book (P/B) ratio of 16.40. Compared to its 3-year average P/B ratio of 29.69, the current P/B ratio is approximately -44.76% higher. Relative to its 5-year average P/B ratio of 35.14, the current P/B ratio is about -53.34% higher. Halozyme Therapeutics Inc (HALO) has a Forward Free Cash Flow (FCF) yield of approximately 7.29%. Compared to its 3-year average FCF yield of 6.54%, the current FCF yield is approximately 11.33% lower. Relative to its 5-year average FCF yield of 5.43%, the current FCF yield is about 34.06% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for HALO competitors is 56.48, providing a benchmark for relative valuation. Halozyme Therapeutics Inc Corp (HALO.O) exhibits a P/S ratio of 5.21, which is -90.77% above the industry average. Given its robust revenue growth of 51.60%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of HALO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of HALO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is HALO currently overvalued or undervalued?

Halozyme Therapeutics Inc (HALO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 9.25 is considered Undervalued compared with the five-year average of 14.38. The fair price of Halozyme Therapeutics Inc (HALO) is between 97.35 to 151.68 according to relative valuation method. Compared to the current price of 69.40 USD, Halozyme Therapeutics Inc is Undervalued By 28.71%.

What is Halozyme Therapeutics Inc (HALO) fair value?

HALO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Halozyme Therapeutics Inc (HALO) is between 97.35 to 151.68 according to relative valuation method.

How does HALO's valuation metrics compare to the industry average?

The average P/S ratio for HALO's competitors is 56.48, providing a benchmark for relative valuation. Halozyme Therapeutics Inc Corp (HALO) exhibits a P/S ratio of 5.21, which is -90.77% above the industry average. Given its robust revenue growth of 51.60%, this premium appears sustainable.

What is the current P/B ratio for Halozyme Therapeutics Inc (HALO) as of Mar 04 2026?

As of Mar 04 2026, Halozyme Therapeutics Inc (HALO) has a P/B ratio of 16.40. This indicates that the market values HALO at 16.40 times its book value.

What is the current FCF Yield for Halozyme Therapeutics Inc (HALO) as of Mar 04 2026?

As of Mar 04 2026, Halozyme Therapeutics Inc (HALO) has a FCF Yield of 7.29%. This means that for every dollar of Halozyme Therapeutics Inc's market capitalization, the company generates 7.29 cents in free cash flow.

What is the current Forward P/E ratio for Halozyme Therapeutics Inc (HALO) as of Mar 04 2026?

As of Mar 04 2026, Halozyme Therapeutics Inc (HALO) has a Forward P/E ratio of 9.25. This means the market is willing to pay $9.25 for every dollar of Halozyme Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Halozyme Therapeutics Inc (HALO) as of Mar 04 2026?

As of Mar 04 2026, Halozyme Therapeutics Inc (HALO) has a Forward P/S ratio of 5.21. This means the market is valuing HALO at $5.21 for every dollar of expected revenue over the next 12 months.

HALO Valuation